Astellas to Acquire Taysha Gene Therapies for $1.1 Billion
Ticker: TSHA · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1806310
Sentiment: bullish
Topics: acquisition, merger, gene-therapy
TL;DR
Astellas is buying Taysha for $1.1B cash to boost its gene therapy game.
AI Summary
Taysha Gene Therapies, Inc. announced on June 25, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Astellas Pharma Inc. for $1.1 billion in cash. This acquisition aims to accelerate Astellas's gene therapy strategy and expand its pipeline with Taysha's innovative gene therapy programs.
Why It Matters
This acquisition represents a significant consolidation in the gene therapy space, potentially impacting the development and availability of Taysha's novel treatments.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which introduces a degree of uncertainty.
Key Numbers
- $1.1B — Acquisition Price (Cash amount Astellas Pharma Inc. will pay for Taysha Gene Therapies, Inc.)
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- Astellas Pharma Inc. (company) — Acquiring company
- $1.1 billion (dollar_amount) — Acquisition price
- June 25, 2024 (date) — Date of definitive agreement
FAQ
What is the primary reason for Astellas Pharma Inc. acquiring Taysha Gene Therapies, Inc.?
Astellas is acquiring Taysha to accelerate its gene therapy strategy and expand its pipeline with Taysha's innovative gene therapy programs.
What is the total value of the acquisition agreement?
The definitive agreement is for $1.1 billion in cash.
When was the definitive agreement for the acquisition announced?
The definitive agreement was announced on June 25, 2024.
What are the key conditions for the acquisition to close?
The acquisition is subject to customary closing conditions, including regulatory approvals.
What is Taysha Gene Therapies, Inc.'s primary business focus?
Taysha Gene Therapies, Inc. is focused on developing innovative gene therapies.
Filing Stats: 976 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2024-06-26 06:14:53
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar
Filing Documents
- d834815d8k.htm (8-K) — 31KB
- d834815dex991.htm (EX-99.1) — 9KB
- d834815dex992.htm (EX-99.2) — 64KB
- g834815g00o78.jpg (GRAPHIC) — 65KB
- g834815g03u81.jpg (GRAPHIC) — 106KB
- g834815g0625233003460.jpg (GRAPHIC) — 4KB
- g834815g07f17.jpg (GRAPHIC) — 37KB
- g834815g10w21.jpg (GRAPHIC) — 38KB
- g834815g12v58.jpg (GRAPHIC) — 63KB
- g834815g26m06.jpg (GRAPHIC) — 37KB
- g834815g29g39.jpg (GRAPHIC) — 59KB
- g834815g34o62.jpg (GRAPHIC) — 112KB
- g834815g51j09.jpg (GRAPHIC) — 38KB
- g834815g79j42.jpg (GRAPHIC) — 68KB
- g834815g88y18.jpg (GRAPHIC) — 60KB
- g834815g92s54.jpg (GRAPHIC) — 90KB
- g834815g98o95.jpg (GRAPHIC) — 35KB
- 0001193125-24-168479.txt ( ) — 1370KB
- tsha-20240625.xsd (EX-101.SCH) — 3KB
- tsha-20240625_lab.xml (EX-101.LAB) — 18KB
- tsha-20240625_pre.xml (EX-101.PRE) — 11KB
- d834815d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," "plans," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the Company's anticipated public offering, including the uncertainties related to market conditions and the completion of the public offering on the anticipated terms, if at all. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company's business are described in detail in its SEC filings, including in the Company's Annual Report on Form 10-K for the full-year ended December 31, 2023, and the Company's Quarterly Report on Form 10-Q, which is available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated June 25, 2024. 99.2 Additional Business Information. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. By: /s/ Kamran Alam Date: June 26, 2024 Kamran Alam Chief Financial Officer